The Quantellect read.As of Nov 19, 2026, 8 active firms cover Q32 Bio Inc: 8 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. The target range is very wide, $14.00 to $66.00 (about 4.7x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $37.00 sits 334% above the current $8.52. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 6 to 8 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.41 next quarter toward $-2.16 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS8 active firms
Buy
Strong Buy00%
Buy8100%
Neutral00%
Sell00%
Strong Sell00%
Based on 8 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$37.00
+334.3% upside
Average target across 7 active firms as of Nov 19, 2026 vs $8.52 current
Highest Target$66.00
Average Target$37.00
Lowest Target$14.00
Detailed analyst forecasts for QTTB
Showing 1–7 of 7 named analysts shown · 8 active firms in the rating projection
As of Nov 19, 2026, 8 of 8 active firms rate QTTB a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
QTTB EPS & revenue forecast
EPS · NEXT QUARTER
$-0.41
Range $-0.43 – $-0.40 · 2 analysts · -23% YoY
Next period, 2 analysts expect Q32 Bio Inc to earn $-0.41 a share (range $-0.43 – $-0.40), versus $-0.54 a year earlier. Full-year consensus is $-1.40, growing to $-2.16 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 2 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $333.3K, rising to $833.3K next year.
Top analysts covering Q32 Bio Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on QTTB.
#1
Yatin Suneja
Guggenheim · Rank #84
Neutral
No targeton QTTB
Overall win rate
50%
+ Follow
#2
Joseph Pantginis
HC Wainwright & Co. · Rank #373
Buy
$36.00+322.5% to target
Overall win rate
34%
+ Follow
#3
Thomas Smith
Leerink Partners · Rank #412
Neutral
$9.00+5.6% to target
Overall win rate
41%
+ Follow
#4
Derek Archila
Wells Fargo · Rank #481
Buy
$59.00+592.5% to target
Overall win rate
36%
+ Follow
#5
Jay Olson
Oppenheimer · Rank #484
Buy
$40.00+369.5% to target
Overall win rate
31%
+ Follow
QTTB stock forecast FAQ
What is QTTB's average 12-month price target?+
The 7 active firms with a live target average $37.00 for Q32 Bio Inc over the next 12 months, ranging from a $66.00 high to a $14.00 low, as of Nov 19, 2026.
Is QTTB stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 8 active firms as of Nov 19, 2026, 8 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for QTTB?+
The Street-high target is $66.00 (Wells Fargo), and the Street-low is $14.00 (Mizuho). The average of all 7 active-firm targets is $37.00.
How many active Wall Street firms cover QTTB?+
8 active firms have a recognized rating on Q32 Bio Inc as of Nov 19, 2026, and 7 active firms carry a live 12-month price target.
Who is the most accurate analyst covering QTTB?+
Among analysts who currently cover QTTB, Yatin Suneja of Guggenheim has the strongest overall Quantellect track record (Rank #84). Their current call is Neutral.
What is Q32 Bio Inc's projected EPS for next quarter?+
The consensus estimate is $-0.41 per share (range $-0.43 – $-0.40) across 2 analysts. Full-year EPS is projected at $-1.40, rising to $-2.16 the following year.
How much revenue is Q32 Bio Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $333.3K, growing to $833.3K next year.
Have analysts been upgrading or downgrading QTTB lately?+
As of Nov 19, 2026, 8 of 8 active firms rate QTTB a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their QTTB calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.